^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Mepact (mifamurtide)

i
Other names: CGP 19835, CGP 19835A, MLV 19835A, L-MTP-PE, liposomal MTP-PE, MTP-PE
Company:
Medison, Takeda
Drug class:
Macrophage stimulant, Monocyte stimulant
6d
SARCOME13: Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (clinicaltrials.gov)
P2, N=60, Active, not recruiting, UNICANCER | Trial primary completion date: Oct 2024 --> Mar 2025
Trial primary completion date • Metastases
|
doxorubicin hydrochloride • Mepact (mifamurtide)
3ms
Chondrosarcoma Co-Culture 3D Model─An Insight to Evaluate Drugs Acting on TAMs. (PubMed, ACS Biomater Sci Eng)
Finally, mifamurtide, an immunomodulator acting on TAMs, was evaluated on the most in vitro relevant model: 3D co-culture CH2879 model. Our results showed that it is now possible to develop 3D models that very accurately mimic what is found in vivo with the possibility of evaluating treatments specific to a tumor cell component.
Journal
|
PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • MMP9 (Matrix metallopeptidase 9)
|
Mepact (mifamurtide)
3ms
Micros: Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Istituto Ortopedico Rizzoli | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule)
|
Mepact (mifamurtide)
8ms
Micros: Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Istituto Ortopedico Rizzoli | Trial primary completion date: Dec 2023 --> Jun 2024
Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule)
|
Mepact (mifamurtide)
10ms
Enrollment closed
|
doxorubicin hydrochloride • Mepact (mifamurtide)
1year
Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma. (PubMed, Cancers (Basel))
We provide experimental evidence that the synergic use of an anti-IL-10 antibody in combination with mifamurtide causes a significantly increased mortality rate in highest-grade OS cells and lower metastasis in an in vivo model compared with mifamurtide alone. Overall, our data suggest that mifamurtide in combination with an anti-IL-10 antibody could be proposed as a new treatment protocol to be studied to improve the outcomes of OS patients.
Journal • Metastases
|
IL10 (Interleukin 10)
|
Mepact (mifamurtide)
over1year
Micros: Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Istituto Ortopedico Rizzoli | Trial completion date: Dec 2021 --> Jun 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule)
|
Mepact (mifamurtide)
2years
Long-Term Outcome of Patients with Follicular Lymphoma Is Not Fundamentally Affected By KMT2D, EZH2, and Crebbp Mutational Status (ASH 2022)
Initial treatment in this series of 295 patients with FL included monoclonal antibody + chemotherapy (57%), single-agent rituximab (15%), chemotherapy (2%), radiotherapy alone (8%), and other treatments (6%). Exploratory analysis with WES was performed on 16 FLEP cases and 10 FLLP cases. There were no significant differences in the occurrence of gene mutations between FLEP and FLLP cases in the WES cohort. Only 1 gene, SETD1B, appeared in the WES panel that is not covered in the HemePACT and clinical IMPACT targeted signaling platforms.
Clinical • IO biomarker
|
KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein)
|
KMT2D mutation • EZH2 mutation • CREBBP mutation
|
Rituxan (rituximab) • Mepact (mifamurtide)
over2years
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2). (PubMed, Cancer)
This study showed that adjuvant mifamurtide, combined with HDIFO for a poor response to induction chemotherapy, could improve EFS in Pgp+ patients. Overall, the outcomes compared favorably with previous series. Mifamurtide and HDIFO as salvage chemotherapy are worth further study.
P2 data • Retrospective data • Clinical Trial,Phase II • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
ABCB1 expression • PGP overexpression
|
cisplatin • doxorubicin hydrochloride • ifosfamide • methotrexate • Mepact (mifamurtide) • methotrexate IV
over2years
Use of an anti-IL-10 antibody to improve Mifamurtide efficacy on aggressive osteosarcoma cells (AACR 2022)
Here, we provide experimental evidence that the addition of an anti-IL-10 antibody to Mifamurtide causes a significant death rate in more aggressive osteosarcoma cells and lower metastasis, compared to Mifamurtide only. In conclusion, considering our data, it could be proposed a new treatment protocol for metastatic osteosarcoma that includes the use of an anti-IL10 antibody integrated with the administration of Mifamurtide to increase its effectiveness in this clinical context.
Clinical
|
IL10 (Interleukin 10)
|
Mepact (mifamurtide)
3years
Micros: Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Istituto Ortopedico Rizzoli | Trial completion date: Jul 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule)
|
Mepact (mifamurtide)
over3years
Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer. (PubMed, Mol Diagn Ther)
We identified potential immunotherapeutic agents based on prognostic gene signature: hexamethonium bromide and isoflupredone. Several novel candidate drugs were suggested, including human interferon-α-2b, paclitaxel, imiquimod, MESO-DAP1, and mifamurtide. These biomolecules and repurposed drugs may be utilised for prognosis and treatment for better survival.
Journal • IO biomarker
|
RIPK2 (Receptor Interacting Serine/Threonine Kinase 2)
|
paclitaxel • Zyclara (imiquimod) • Mepact (mifamurtide)
over3years
[VIRTUAL] ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastaticextremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials. (ASCO 2021)
Preoperatively, all patients received methotrexate, adriamycin, cisplatinum (MAP)...In case of Pgp overexpression (Pgp+), mifamurtide (2 mg/m2 twice/week for 3 months then weekly for 6 months) was added after surgery, with 4 consecutive cycles of ifosfamide 3 gr/m2/day, day 1-5 (HDIFO) in case of poor histologic response (necrosis < 90%) to MAP... In this prospective uncontrolled study with a risk-adapted strategy for non-metastatic osteosarcoma, survival is superior to that of all ISG/GEIS previous series . The 3-year EFS of 71.9% compares favorably with other reports . Pgp+ patients performed well in this study, in which mifamurtide and HDIFO were added after a poor response to MAP.
Clinical
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
ABCB1 overexpression
|
cisplatin • doxorubicin hydrochloride • ifosfamide • Mepact (mifamurtide)
over3years
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma (clinicaltrials.gov)
P2/3, N=225, Active, not recruiting, Italian Sarcoma Group | Trial completion date: Mar 2021 --> Oct 2021 | Trial primary completion date: Mar 2021 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
ABCB1 overexpression
|
cisplatin • doxorubicin hydrochloride • ifosfamide • Mepact (mifamurtide)
over3years
The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications. (PubMed, Cell Oncol (Dordr))
TAMs may participate in the malignant progression of osteosarcoma through self-polarization, the promotion of blood vessel and lymphatic vessel formation, immunosuppression, and drug resistance. Besides, various immune checkpoint proteins expressed on the surface of TAMs, such as PD-1 and CD47, provide the possibility of the application of immune checkpoint inhibitors. Several clinical trials have been carried out and/or are in progress. Mifamotide and the immune checkpoint inhibitor Camrelizumab were both found to be effective in prolonging progression-free survival. Thus, TAMs may serve as attractive therapeutic targets. Targeting TAMs as a complementary therapy is expected to improve the prognosis of osteosarcoma. Further efforts may be made to identify potential beneficiaries of TAM-targeted therapies.
Review • Journal
|
PD-1 (Programmed cell death 1) • CD47 (CD47 Molecule)
|
AiRuiKa (camrelizumab) • Mepact (mifamurtide)
over4years
[VIRTUAL] ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2) (ESMO 2020)
Preoperatively, all patients received MAP (methotrexate, adriamycin, platinum). In case of Pgp overexpression (Pgp+), mifamurtide (2 mg/m2 twice/week for 3 months than weekly for 6 months) was added after surgery, with 4 consecutive cycles of ifosfamide 3 gr/m2/day, day 1-5 (HDIFO) in case of poor response (PR) to MAP...Funding: The Onlus Association “Il Pensatore - Matteo Amitrano”; Fondazione Carisbo Clinical and Translational Research Grant 2019. Clinical trial identification: NCT01459484; Eudract: 2011-001659-36.
Clinical
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
ABCB1 overexpression
|
doxorubicin hydrochloride • ifosfamide • methotrexate • Mepact (mifamurtide)
almost5years
Clinical • Enrollment change
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
ABCB1 overexpression
|
cisplatin • doxorubicin hydrochloride • ifosfamide • Mepact (mifamurtide)